Mifepristone protects acetaminophen induced liver injury through nrf2/gsh/gst mediated ferroptosis suppression
Foviscu (WCK 4282) - Phase 3 Ongoing First-line empiric treatment for gram-negative hospital infections (cUTI, HABP/VABP) Complements ZAYNICH: while ZAYNICH is the destination therapy at the top of the pyramid for resistant infections, Foviscu is the entry-level, broad-use first drug of choice Global Phase 3 trial underway If approved, the commercial TAM is significantly larger than ZAYNICH due to broader use 5
The connection between sleep, stress, and GLP-1 medication effects goes beyond sulfur burps
UK healthcare professionals follow NICE guidance recommending single-agent pharmacotherapy alongside lifestyle modifications
I learned a lot about how technology, that is intended to make things easier, can have unintended impacts, so thoughtful technology is the ask